Last $117.51 USD
Change Today 0.00 / 0.00%
Volume 0.0
ALIOF On Other Exchanges
SIX Swiss Ex
As of 8:10 PM 09/18/14 All times are local (Market data is delayed by at least 15 minutes).

actelion ltd-reg (ALIOF) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/3/14 - $129.25
52 Week Low
10/9/13 - $65.57
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ACTELION LTD-REG (ALIOF)

Related News

No related news articles were found.

actelion ltd-reg (ALIOF) Related Businessweek News

No Related Businessweek News Found

actelion ltd-reg (ALIOF) Details

Actelion Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for diseases with unmet medical needs. Its products include Tracleer, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH), a chronic and life-threatening disorder that severely compromises the functions of the lungs and heart; Opsumit, an orally available endothelin receptor antagonist; and Valchlor, a chemotherapeutic agent for the treatment of mycosis fungoides, a common type of cutaneous T-cell lymphoma. The company also provides Veletri, a formulation of epoprostenol for the treatment of PAH; Ventavis, an inhaled formulation of iloprost for the treatment of PAH; and Zavesca, an oral treatment for patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is unsuitable. Actelion Ltd markets its products in Switzerland, the United States, Japan, China, Russia, and Mexico. The company was founded in 1997 and is headquartered in Allschwil, Switzerland.

2,396 Employees
Last Reported Date: 02/7/14
Founded in 1997

actelion ltd-reg (ALIOF) Top Compensated Officers

Founder, Chief Executive Officer, Member of M...
Total Annual Compensation: SFr.2.6M
Compensation as of Fiscal Year 2013.

actelion ltd-reg (ALIOF) Key Developments

Actelion Ltd. Presents at UBS Best of Switzerland Conference, Sep-19-2014 01:30 PM

Actelion Ltd. Presents at UBS Best of Switzerland Conference, Sep-19-2014 01:30 PM. Venue: Wolfsberg Conference Center, Ermatingen, Switzerland. Speakers: Andrew Weiss, Head of Investor Relations and Corporate Communications, Otto Schwarz, Chief Operating Officer, Executive Vice President and Member of the Management Board.

Investors Reportedly Eyes Stake In InterMune

Sanofi SA-(Sanofi AG) and Roche Holding AG (SWX:ROG) are the bidders to acquire InterMune, Inc. (NasdaqGS:ITMN), people with knowledge of the matter said. Also bidding for InterMune are GlaxoSmithKline plc (LSE:GSK) and Actelion Ltd. (SWX:ATLN), said the people, asking not to be identified because the process is private. Sanofi has so far shown the most interest in a deal, one person said. Goldman Sachs Group Inc. and Centerview Partners LLC are helping InterMune sort through bids for the business, the people said. Representatives for InterMune, Sanofi (SAN), Actelion, Roche, GlaxoSmithKline, and Goldman Sachs declined to comment. Representatives for Centerview couldn’t be reached. Shares of InterMune went up by 14% to $52.06.

Actelion Reports Earnings Results for the First Half Ended June 2014; Provides Earnings Guidance for the Year 2014

Actelion reported product sales for the first half of 2014. The company has reported 12% year-on-year growth in product sales for the first half of 2014, or a 17% year-on-year increase in constant currencies, amounting to CHF 993 million (USD 1.1 billion) in product sales. The company's pulmonary arterial hypertension drug Tracleer (bosentan) continued to be its top-selling product, with sales rising by 3% year-on-year to CHF 791 million. In terms of the firm's other products, sales of blood pressure drug Ventavis (iloprost) increased 10% year-on-year to CHF 58 million, sales of Gaucher's disease drug Zavesca (miglustat) grew 13% year-on-year to CHF 54 million, and sales of cardiovascular drug Veletri (epoprostenol for injection) increased 112% year-on-year to CHF 31 million. Core earnings had increased to CHF 421 million. Operating income increased by 42% in local currency to reach CHF 347 million. Fully diluted core earnings per share for the first half of 2014 amounted to CHF 3.25 compared to CHF 2.34 during the same period last year. Net income of CHF 420 million, an increase of 126% in local currencies. Cash from operations, excluding the Asahi impact, continues to be strong at CHF 259 million. For the year 2014, the company expects 2014 core earnings growth to be at least in the mid-teen percentage range at constant exchange rate. This upgraded guidance is a result of a higher product contribution and the positive impact of U.S. rebate reversals. Removing this impact, the company now expects 2014 core earnings growth to be at least in the low double-digit territory against at local currency and unforeseen events excluded. This very strong 2014 performance will set a significantly higher base for 2015, and the company will therefore review its guidance early 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALIOF:US $117.51 USD 0.00

ALIOF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioMarin Pharmaceutical Inc $69.85 USD +0.25
Ipsen SA €39.81 EUR +1.19
Meda AB kr101.50 SEK +2.40
Orion OYJ €30.00 EUR +0.84
United Therapeutics Corp $130.12 USD -0.81
View Industry Companies

Industry Analysis


Industry Average

Valuation ALIOF Industry Range
Price/Earnings 18.1x
Price/Sales 6.2x
Price/Book 6.4x
Price/Cash Flow 16.4x
TEV/Sales 5.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACTELION LTD-REG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at